Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different doses of rabbit antithymocyte immunoglobulin for GVHD prophylaxis in pediatric HSCT
2008-000101-11Phase 3Active
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Cumulative incidence of acute GVHD (grade II–IV). Started Feb 2008; status: active.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2008-000101-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000101-11.